摘要
目的:探讨替吉奥(S-1)胶囊联合吉西他滨(GEM)化疗与吉西他滨单药治疗进展期胰腺癌的疗效。方法:对2011年5月至2013年5月收治的37例晚期胰腺癌患者的临床资料进行回顾性分析,其中18例采用替吉奥胶囊联合吉西他滨方案治疗(治疗组);19例采用吉西他滨单药治疗(对照组)。采用KaplanMeier法分析患者的生存时间,并比较两组患者的客观缓解率、临床受益反应(CBR)、中位疾病进展时间、中位生存时间和不良反应。结果:治疗组有效率明显高于对照组(33.3%vs 21.1%),差异有统计学意义(P=0.032)。治疗组疾病控制率(DCR)高于对照组(72.2%vs 63.2%),但差异无统计学意义(P=0.450)。治疗组患者CBR缓解率高于对照组(71.8%vs 45.7%),差异无统计学意义(P=0.421)。治疗组的中位生存时间为10.1个月(95%CI:8.0-11.5个月),高于对照组的8.02个月(95%CI:3.7-10.8个月),差异有统计学意义(P=0.043);两组的中位疾病进展时间分别为3.5个月和3.0个月(P=0.720)。治疗组的6个月生存率(72.5%)略高于对照组(66.5%),但差异无统计学意义(P>0.05)。两组不良反应的发生率也相似(P>0.05)。结论:替吉奥胶囊联合吉西他滨治疗方案与单药治疗晚期胰腺癌相比,在客观疗效、中位生存时间方面表现出一定优势,疾病控制率及临床受益反应也有所提高,且不良反应可耐受,是晚期胰腺癌的有效治疗方案。
Objective： To compare the efficacy of Gimeracil and Oteracil Porassium capsules（ S- 1） plus GEM and GEM alone on advanced pancreatic cancer. Methods： From May 2011 to May 2013,37 patients of advanced pancreatic cancer（ APC） were analyzed retrospectively. Of 37 APC patients,18 received GEM and S- 1（ treatment group）,19 received GEM（ control group）. The survival was analyzed by Kaplan- Meier method. Overall survival rate,clinical benefit response（ CBR）,median time to progression（ m TTP）,median overall survival（ m OS） and adverse events were assessed according to World Health Organization criteria. Results： The combination group（ treatment group） efficient was obviously higher than Gemcitabine single drug group（ control group）（ 33. 3% vs. 21. 1%,P = 0. 032）. The disease control rates（ DCR） was 72. 2% in the treatment group and 63. 2% in the control group,there was no significant difference in the DCR（ P = 0. 450）. The CBR was 71. 8% in the treatment group and 45. 7%in the control group,there was no significant difference in the CBR（ P = 0. 421）. The treatment group median survival time was 10. 1 months（ 95% CI： 8. 0- 11. 5 months）,higher than the control group 8. 0 2 months（ 9 5 % CI ： 3. 7- 10. 8 months）,there was significant difference between the two groups in the median survival time（ P = 0. 043）;two groups of median time to progression were 3. 5 months and 3. 0 months（ P = 0. 720）. The six months survival rate was 72. 5% in the treatment group and 66. 5% in the control group,there was no significant difference in the six months survival rate（ P 0. 05）. There was no significant difference in adverse events between the two groups（ P 0. 05）. Conclusion： The combination S- 1 and Gemcitabine chemotherapy can increase the survival rate and appears to be a beneficial treatment for patients with advanced pancreatic cancer.
出处
《现代肿瘤医学》
CAS
2014年第12期2921-2923,共3页
Journal of Modern Oncology
关键词
胰腺肿瘤
吉西他滨
替吉奥胶囊
化学疗法
临床受益反应
pancreatic neoplasms
Gemcitabine
Gimeracil and Oteracil Porassium capsules
chemotherapy
clinical benefit response
